Latest Pharmaceuticals News

Page 32 of 44
Whitefield Industrials Limited reported a 10% increase in core operating profit for the year ended March 2025, outperforming its benchmark with a 7.5% portfolio return and raising fully franked dividends to 10.5 cents per share.
Claire Turing
Claire Turing
20 May 2025
Clarity Pharmaceuticals has initiated its second registrational Phase III AMPLIFY trial for the Cu-SAR-bisPSMA PET imaging agent targeting biochemical recurrence of prostate cancer. The multi-centre study aims to generate critical data supporting FDA approval and could redefine prostate cancer diagnostics.
Ada Torres
Ada Torres
20 May 2025
Avecho Biotechnology has expanded its pivotal Phase III clinical trial for a CBD insomnia treatment by adding new recruitment sites and partnering with pharmaceutical giant Sandoz to boost patient enrolment and regulatory progress.
Ada Torres
Ada Torres
20 May 2025
Mayne Pharma has sent out the Scheme Booklet to shareholders, marking a key step in the proposed acquisition by Cosette. The booklet includes critical details to guide shareholder decisions ahead of the upcoming Scheme Meeting.
Victor Sage
Victor Sage
20 May 2025
Recce Pharmaceuticals has successfully raised A$8.4 million through an entitlement offer and placement to fund pivotal Phase 3 clinical trials, advancing its synthetic anti-infective pipeline towards commercialisation in 2026.
Ada Torres
Ada Torres
16 May 2025
Mayne Pharma Group has proposed a $7.40 per share acquisition by Cosette Pharmaceuticals, with unanimous board support and a fair and reasonable opinion from an independent expert. Shareholders will vote on the scheme on June 18, 2025.
Ada Torres
Ada Torres
15 May 2025
Sigma Healthcare has released its standalone annual and sustainability reports for the year ending January 2025, marking the final disclosures before its merger with Chemist Warehouse Group in February 2025.
Ada Torres
Ada Torres
15 May 2025
Mayne Pharma has voluntarily withdrawn a speaker presentation for its contraceptive NEXTSTELLIS® following an FDA Untitled Letter concerning promotional claims. The company confirms this does not impact sales or its planned merger with Cosette.
Victor Sage
Victor Sage
14 May 2025
Mayne Pharma has addressed a sharp share price decline following the public release of an FDA Untitled Letter, confirming no undisclosed material information and reaffirming compliance with ASX rules.
Ada Torres
Ada Torres
14 May 2025
Neuren Pharmaceuticals has received official FDA minutes confirming the primary endpoints for its pivotal Phase 3 trial of NNZ-2591 targeting Phelan-McDermid syndrome, reinforcing the positive signals from earlier studies.
Ada Torres
Ada Torres
13 May 2025
Botanix Pharmaceuticals has clarified that recent share price movements are linked to a rumored US executive order on drug pricing, confirming no undisclosed material information. The company reassures investors of compliance with ASX disclosure rules amid market speculation.
Ada Torres
Ada Torres
12 May 2025
Botanix Pharmaceuticals clarifies its lead product Sofdra is unlikely to face price cuts under the proposed US executive order on drug pricing, citing its exclusive US market approval and distinct formulations abroad.
Ada Torres
Ada Torres
12 May 2025